Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

re information about Alexza, the Staccato system technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

The anticipated news release and conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Paragon 28, Inc . ... of its foot plating system that supplants the Normed ... TM R3CON PLATING SYSTEM greatly enhances the product ... & Mini-Monster TM Screw Systems and Preserve TM ... interchangeable subsystems, the GORILLA TM R3CON SYSTEM offers ...
(Date:9/22/2014)... , Sept. 22, 2014 The western ... stage. It is largely a replacement market with ... The mergers, acquisitions and partnerships are redefining competitive ... This research service provides details about revenue forecasts, ... pricing trends across the country. The changing landscape ...
(Date:9/22/2014)... September 22, 2014 ... has announced the addition of the  "Global ... & Industrial) Market - Forecast to 2019" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The global freeze drying market ... and is expected to reach at $2,655.9 ...
Breaking Medicine Technology:Paragon 28, Inc. Launches the GORILLA(TM) R3CON PLATING SYSTEM 2Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 2Global Freeze Drying / Lyophilization Equipment (Lab, Pilot, & Industrial) Market - Forecast to 2019 3
... ANN ARBOR, Mich., Feb. 6, 2012  Adeona Pharmaceuticals, Inc. ... synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious ... Director appointments to strengthen and expand the Company,s leadership, ... of the Adeona Board of Directors since March 2010 ...
... Feb. 6, 2012  EntreMed, Inc. (Nasdaq: ENMD ), ... cancer, announced today that Wei-Wu He, Ph.D has joined the ... Ph.D has joined as a member of the Board of ... Dr. Wei-Wu He is currently the CEO and Chairman of ...
Cached Medicine Technology:Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 2Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 3Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 4Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus 5Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 2Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 3Biotech Leaders Wei-Wu He, Ph.D and Tak W. Mak, Ph.D Join EntreMed's Board of Directors 4
(Date:9/23/2014)... September is Self-Improvement Month and the ... people improve their lives every day. This month long ... small to make improvements in their lives. The idea ... lives and make easy adjustments towards their goals. Whether ... or getting on track with finances, this month is ...
(Date:9/23/2014)... Computer Resources of America, Inc. (CRA), ... York City, has been awarded the contract to deploy ... in the NY Metro geography for a large, global ... corporate and trading floor midtown and Jersey City locations, ... NY Metro disaster recovery locations. The bank is ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 The Nordic ... aggregator founded by MediaBuzz ApS, a Danish media company ... Nordic Times works with cutting-edge news, blogs, social feeds, ... news, EU news, and news from around the world. ... Viral Content – acknowledging the way that virality has ...
(Date:9/23/2014)... 23, 2014 Today Bibliomotion ... by Bringing Life to Work: A Guide for ... In the book, Brower proves that organizations accomplish the ... policies, and informal cultural practices that help employees integrate ... research shows that the investment will pay significant dividends ...
(Date:9/23/2014)... Rinovum Women’s Health announced today that ... the market cleared by the FDA for over-the-counter sales—is ... http://www.storkotc.com . , For the one in six ... is delayed by infertility1 or other issues, The Stork ... chances to conceive. It is the only FDA-cleared ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Celebrating Self-Improvement Month by Giving Away a Foot Massager 2Health News:Emassagechair.com is Celebrating Self-Improvement Month by Giving Away a Foot Massager 3Health News:Launching of The Nordic Times, a new online newspaper and aggregator. 2Health News:Tracy Brower ‘Brings Work to Life’ in Her New Book, Published By Bibliomotion 2Health News:Tracy Brower ‘Brings Work to Life’ in Her New Book, Published By Bibliomotion 3Health News:Tracy Brower ‘Brings Work to Life’ in Her New Book, Published By Bibliomotion 4Health News:Tracy Brower ‘Brings Work to Life’ in Her New Book, Published By Bibliomotion 5Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 2Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 3Health News:First-Ever Conception Assistance Device FDA-Cleared for Home Use Launches U.S. OTC Sales -- The Stork® OTC Delivers Hope to Millions Struggling to Conceive A Child 4
... increasing day by day. The number of infections a person ... risk of death from heart attack. It is long been ... heart disease.// This has been possible by promoting inflammation within ... so far, have conflicting evidence. ,According to researchers ...
... are affected with depression are more likely to die of ... Dr. Robert M. Carney at Washington University School of Medicine ... tend to have poor heart rate variability (HRV). ,Heart ... to contract, which can affect its ability to handle stress ...
... of patients on long-term non-steroidal anti-inflammatory drug (NSAID) ... infection can substantially reduce the risk of ulcer ... per cent of H.pylori infections and reduced the ... in the control group to 12 per cent ...
... new ray of hope for hearing impairment. A new hearing ... sound quality than a more conventional aid. Doctors say that ... usual kind of hearing aid transmits sound through the eardrum, ... as well as giving the wearer the feeling of talking ...
... reason why people go to the doctor. Antibiotics are worthless ... developed a drug that speeds recovery from the common cold ... pursuit of a cure for decades. The new drug, ... eases cold symptoms within a day and makes a runny ...
... when it comes to dealing with women's health issues. The ... moves to tackle diseases affecting women, including heart disease and ... government have done either too little or nothing at all ... ,Neither the nation nor the states have ...
Cached Medicine News:
... The PANBIO Inc. Indirect Fluorescence ... (ANA) HEp2 is intended for the ... (Immunoglobulin G) antinuclear antibodies in human ... can be used as an aid ...
Anti-Tg and Anti-TPO are two major autoantibodies implicated in autoimmune related thyroiditis and aid in the differential diagnosis of Hashimoto's thyroiditis and Graves' disease....
... the medication most commonly prescribed for the prevention ... attacks and strokes. However, a number of studies ... people taking daily aspirin therapy to prevent a ... full benefits. These people are at greater ...
... system provides both pressure and flow ... or in a combined screen format ... and Volcano's unique Doppler FloWire. Physiologic ... tools to assess ambiguous or intermediate ...
Medicine Products: